8-K: Adagio Medical Announces CFO Departure and Provides Business Updates on VT Ablation Technology

Adagio Medical Holdings, Inc. announces the resignation of its CFO, John Dahldorf, while providing updates on its ventricular tachycardia (VT) solutions, including progress on the FULCRUM-VT trial and presentations at the European Heart Rhythm Association Annual Meeting.

Summary

• Adagio Medical Holdings, Inc. announced the resignation of its Chief Financial Officer, John Dahldorf, effective March 21, 2025.
• The company is actively searching for a new CFO and will appoint a transitional CFO in the interim.
• Adagio Medical is focusing on ventricular tachycardia (VT) solutions and will participate in the European Heart Rhythm Association Annual Meeting in Vienna from March 30 to April 1, 2025.
• Presentations at the meeting will highlight the use of the company's ultra-low temperature cryoablation (ULTC) technology for VT and premature ventricular complex (PVC) ablation.
• The FULCRUM-VT IDE Pivotal Study, designed to support US premarket approval of the VT Cryoablation System, is over 40% enrolled and is on track for full patient enrollment in the second half of 2025.
• The FULCRUM-VT study is a prospective, multi-center, open-label, single-arm study enrolling 206 patients with structural heart disease indicated for catheter ablation of drug refractory ventricular tachycardia.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CFO departure is a negative, but the progress on the FULCRUM-VT trial and participation in the European Heart Rhythm Association Annual Meeting are positive developments. The management expresses confidence in the company's ability to achieve its goals.

Positives

• The FULCRUM-VT IDE Pivotal Study is progressing well, with over 40% enrollment achieved.
• Adagio Medical's products are addressing a recognized market need for VT ablation technology.
• The company is participating in a major industry event, the European Heart Rhythm Association Annual Meeting, to showcase its technology.
• The company believes it has the financial resources and corporate structure to achieve its goals.

Negatives

• The departure of the CFO, John Dahldorf, creates uncertainty in the company's financial leadership.
• A transitional CFO will be appointed, which may cause some disruption.

Risks

• The company's forward-looking statements are subject to risks, uncertainties, and other factors that may cause actual results to differ materially.
• The company cautions that its forward-looking statements are based on estimates and assumptions that are inherently uncertain.
• The company's success depends on the successful completion of the FULCRUM-VT trial and subsequent regulatory approval.

Future Outlook

The company is focused on completing the FULCRUM-VT trial and obtaining US premarket approval for its VT Cryoablation System. They are also focused on product design optimization.

Management Comments

• Todd Usen, CEO, is pleased with the FULCRUM-VT enrollment progress and the expanded use of the vCLAS catheter.
• Todd Usen believes the company's products address a market need for VT ablation technology.
• Todd Usen thanked John Dahldorf for his support and wished him the best.
• Todd Usen stated that the company has the financial resources and corporate structure to achieve its goals.

Industry Context

Adagio Medical is operating in the competitive medical device industry, specifically targeting the cardiac arrhythmia market with its cryoablation technology. The company's focus on VT ablation aligns with the growing need for effective treatments for this condition.

Comparison to Industry Standards

• Companies like Medtronic, Abbott, and Boston Scientific also compete in the cardiac ablation market, offering various technologies including radiofrequency ablation and cryoablation.
• Adagio Medical's ULTC technology aims to create contiguous, transmural lesions, which is a key factor in the effectiveness of ablation procedures.
• The FULCRUM-VT trial's design, enrolling 206 patients, is comparable to other pivotal trials in the cardiac device space seeking regulatory approval.
• The presentations at the European Heart Rhythm Association Annual Meeting provide a platform for Adagio Medical to showcase its technology alongside other industry leaders.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the CFO departure but encouraged by the progress on the FULCRUM-VT trial.
• Employees may experience some uncertainty during the CFO transition.
• Physicians and patients may benefit from the company's VT ablation technology.
• The company's suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• Continue enrollment in the FULCRUM-VT IDE Pivotal Study.
• Participate in the European Heart Rhythm Association Annual Meeting.
• Appoint a transitional CFO and search for a permanent replacement.
• Pursue US premarket approval of the VT Cryoablation System with the vCLAS catheter.

Key Dates